Product name

Summary

Organization name

Profile

Diagnosis of stroke is done through clinical neurological examination and confirmed with assistance from imaging techniques like CT or MRI scans. Such techniques are subject to interpretation and often unable to detect the most common form of stroke until 12 to 24 hours after an event. Moreover, an early diagnosis and therapy of stroke is of importance to avoid a negative clinical outcome.

At the Universities of Goettingen and Erlangen/Nuernberg scientists identified a novel biomarker for a blood based test, which should be useful in clinical practice, which is quickly measured in plasma, and which plasma concentration seems to depend on the dimension of infarcted brain area and the duration of cerebral ischemia.

Hallmarks

• Method based on blood/plasma samples.
• Use of the Ratio Aß-38/Aß-40 as diagnostic stroke biomarker.
• Good sensitivity and good specificity.
• Tight relationship between plasma Aß-levels and the time course of ischemic brain disorders.
• Different plasma Aß-peptide pattern between patients showing acute cerebral ischemia and other neuropsychiatric and neurodegenerative disorders.

Use

• In urgent diagnosis of stroke.
• For monitoring and supporting the prognosis of stroke patients.

Patents applications have been filde.

The marker was identified at he universities of Goettingen and Erlangen-Nuernberg and is offered for licensing by MBM.

Contact

Dr. Carlos Güntner
cguntner(at)sciencebridge.de

About MBM

MBM ScienceBridge GmbH is the technology transfer organization of the Georg-August University Goettingen.  It is a spin-off of the Competence Center MBM, a technology transfer initiative within Georg-August-University formed in 2001, which was spun off into the MBM ScienceBridge GmbH in 2004. Their focus includes innovations from the areas of Medical and Measurement Technology, Biotechnology, Chemistry, Physics, Information Technology, Forestry and Agriculture.

Description File

URL

Your feedback

back